Terumo (OTCMKTS:TRUMY – Get Free Report) and Lantheus (NASDAQ:LNTH – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.
Profitability This table compares Terumo and Lantheus’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Terumo 12.09% 9.17% 6.57% Lantheus 18.05% 29.32% 15.00% Volatility & Risk Terumo has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.
Analyst Ratings This is a summary of current ratings and target prices for Terumo and Lantheus, as reported by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terumo 0 2 0 0 2.00 Lantheus 0 3 8 0 2.73 Lantheus has a consensus target price of $110.43, suggesting a potential upside of 5.35%. Given Lantheus’ stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Terumo.
Insider & Institutional Ownership 99.1% of Lantheus shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation This table compares Terumo and Lantheus”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Terumo $7.52 billion 2.60 $897.03 million $0.61 21.72 Lantheus $1.54 billion 4.43 $233.56 million $4.15 25.26 Terumo has higher revenue and earnings than Lantheus. Terumo is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Summary Lantheus beats Terumo on 11 of the 14 factors compared between the two stocks.
About Terumo (Get Free Report)
Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.
About Lantheus (Get Free Report)
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEReviewing Fidus Investment (NASDAQ:FDUS) and Invent Ventures (OTCMKTS:IDEA)
NEXT HEADLINE »Comparing Medicure (OTCMKTS:MCUJF) & Takeda Pharmaceutical (NYSE:TAK)
BEDFORD, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to discuss its financial results and provide a business update for the second quarter of 2026.
Leading pharmaceutical executive brings over 4 decades of commercial, M&A, and governance leadership July 15, 2026 13:13 ET | Source: RadioMedix, Inc.
HOUSTON, July 15, 2026 (GLOBE NEWSWIRE) -- RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced the appointment of Brian A. Markison to the company’s board of directors effective July 1, 2026.
"We are thrilled to welcome Brian to our Board as our second independent Director. He brings the kind of valuable experience we need at this important stage of our growth," said Ebrahim S. Delpassand, M.D., Founder and Chief Executive Officer of RadioMedix. "Four decades of leadership across oncology, diagnostics, and radiopharmaceuticals, building and growing leading radiopharmaceutical platforms in the industry, will be invaluable as we advance our cancer theranostic pipeline and manufacturing infrastructure. His depth in commercial strategy, M&A, and corporate governance will be instrumental as we execute on our growth strategy."
Mr. Markison added, “I have spent my career watching the radiopharmaceutical field grow, and RadioMedix is one of the most exciting companies that has contributed to that growth. I am honored to join the Board and look forward to working with the team as they continue to scale their pipeline and manufacturing capabilities to change how cancer is diagnosed and treated.”
Mr. Markison brings more than 40 years of pharmaceutical and radiopharmaceutical leadership to RadioMedix including his previous role as Chief Executive Officer and Director of Lantheus Holdings, Inc. (NASDAQ: LNTH). Earlier in his career, Mr. Markison served as Chairman and Chief Executive Officer of RVL Pharmaceuticals plc (formerly Osmotica Pharmaceuticals), and as President, CEO and Board Member of Fougera Pharmaceuticals Inc., which he led through its strategic sale to Sandoz Ltd., the generics division of Novartis AG. He also served as Chairman and CEO of King Pharmaceuticals, Inc., leading the company through a period of portfolio restructuring and its eventual acquisition by Pfizer Inc. Mr. Markison began his career at Bristol-Myers Squibb, where over a 22-year tenure he held a series of senior leadership roles across oncology, virology, neuroscience, infectious disease, dermatology, as well as licensing and business development and mergers and acquisitions. He holds a Bachelor of Science degree from Iona College.
About RadioMedix
RadioMedix, Inc. is a clinical-stage biotechnology company advancing precision solutions in nuclear medicine with a focus on targeted radiopharmaceuticals for the diagnosis, monitoring, and therapy of hard-to-treat cancers with high unmet need. RadioMedix has achieved two FDA approval of its diagnostic radiopharmaceuticals and 3 licensing deal since its inception. The Company’s pipeline includes best-in-class radiopharmaceuticals for PET imaging and radionuclide therapy, with a focus on progressing the next generation of Targeted Alpha Therapies (TAT). To support its operations, RadioMedix built The SPICA Center, a self-sufficient, state-of-the-art 27,500 sq. ft. facility that is leading the industry in radiopharmaceutical manufacturing and offers full-service support for academic and industry partners. The Spica Center received FDA approval as a cGMP manufacturing site in March of 2026 after passing FDA inspection with NO citations. For more information, visit https://radiomedix.com/ and follow us on LinkedIn.
FDA Issues Complete Response Letter For Lantheus Imaging AgentThe FDA stated unresolved third-party facility manufacturing-related conditions.
The third-party facility is responsible for drug product manufacturing. Satisfactory resolution of the unresolved facility inspection-related conditions is required before the LNTH-2501 NDA may be approved.
The CRL did not identify any concerns regarding the data submitted by Lantheus in support of the application, nor did it identify any issues related to the safety or efficacy of LNTH-2501.
In March, the FDA extended the PDUFA date for LNTH-2501 by three months to June 29, 2026, to allow additional time to review manufacturing-related information.
The agency said that the standard review extension is not related to the efficacy or safety data of LNTH-2501.
William Blair Delays Octevy Sales ForecastWilliam Blair on Monday wrote, “While we are disappointed by the setback, we are encouraged that the complete response letter (CRL) does not appear to be clinical in nature.”
In light of the CRL, analyst Andy Hsieh pushed back initial sales of Octevy by one year in the model to the first quarter of 2028 from the first quarter of 2027 previously.
Octevy is a PET diagnostic imaging agent for certain neuroendocrine tumors.
Analyst Highlights Improving Fundamentals, Growth CatalystsTaking a step back, William Blair wrote that the fundamentals for Lantheus are improving as the company navigates through challenging pricing dynamics before transitioning the market to Pylarify TruVu at the end of the year.
The analyst said that the ongoing launch of Neuraceq, coupled with the anticipated approval of MK-6240 (tau-directed diagnostic PET agent for Alzheimer’s disease), provides multiple drivers to reinvigorate top-line growth.
LNTH Price Action: Lantheus Holdings shares were trading down 0.50% at $109.25 at the time of publication on Monday. The stock is trading near its 52-week high of $111.46, according to Benzinga Pro data.
Image via Shutterstock
Market News and Data brought to you by Benzinga APIs
June 26, 2026 16:01 ET | Source: Lantheus Holdings, Inc.
BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs).
The FDA stated that the agency cannot approve the NDA by the Prescription Drug User Fee Act (PDUFA) action date of June 29, 2026, due to unresolved third-party facility manufacturing-related conditions. The third-party facility is responsible for drug product manufacturing. Satisfactory resolution of the unresolved facility inspection-related conditions is required before the LNTH-2501 NDA may be approved.
The CRL did not identify any concerns regarding the data submitted by Lantheus in support of the application, nor did it identify any issues related to the safety or efficacy of LNTH-2501.
“We remain confident in LNTH-2501 and are committed to bringing this imaging agent to NETs patients and healthcare providers as soon as possible,” said Mary Anne Heino, Executive Chairperson and Chief Executive Officer, Lantheus. “The feedback received from the FDA relates solely to our third-party manufacturer, and not to the clinical performance of the product. We are working closely with our partner and the Agency to address these facility manufacturing-related conditions and advance the program.”
About LNTH-2501 (Ga 68 edotreotide)
LNTH-2501 (Kit for Preparation of Ga 68 edotreotide Injection), is an investigational radioactive diagnostic kit indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. LNTH-2501 is supplied as a 2-vial kit to radiopharmacies which allows for direct preparation of Ga 68 edotreotide injection with the eluate of Gallium from an on-site generator at the radiopharmacy. LNTH-2501 is not currently approved by the FDA and is not yet available for sale in the United States.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include our ability to work with our third-party manufacturing partner to address the feedback outlined in the CRL in order to obtain a positive regulatory outcome from the FDA for LNTH-2501 and the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q).
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842 [email protected]
Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Purchase Licensing Rights, opens new tab
CompaniesJune 26 (Reuters) - The U.S. Food and Drug Administration declined to approve Lantheus Holdings’ (LNTH.O), opens new tab diagnostic imaging kit for types of cancer tumors, citing unresolved issues at a third-party manufacturing facility, the company said on Friday.
This marks another setback for Lantheus, as the health regulator had in March extended its review of the imaging kit, LNTH-2501, by three months.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
The FDA did not identify any concerns regarding the data submitted by Lantheus or the safety and efficacy of LNTH-2501, the company said.
"The feedback received from the FDA relates solely to our third-party manufacturer, and not to the clinical performance of the product," said CEO Mary Anne Heino.
The company is working with the manufacturer and the regulator to address the concerns, Heino said.
LNTH-2501 is a diagnostic radiopharmaceutical kit used with PET scans to detect neuroendocrine tumors, or NETs — cancers that arise in hormone-producing cells in organs such as the lungs, pancreas and digestive tract.
The condition is more common in adults than children, and the slow-growing subtype once known as carcinoid tumor affects about four in every 100,000 adults, according to the National Institutes of Health.
Reporting by Sahil Pandey and Puyaan Singh in Bengaluru; Editing by Sahal Muhammed
Our Standards: The Thomson Reuters Trust Principles., opens new tab
March 17, 2026 16:01 ET | Source: Lantheus Holdings, Inc.
BEDFORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has extended its review of the New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide) by three months to June 29, 2026.
The extension and revised target Prescription Drug User Free Act (PDUFA) goal date of June 29, 2026, will allow the FDA additional time to review and consider further manufacturing related information submitted by Lantheus. This standard review extension is not related to the efficacy or safety data of LNTH-2501.
About LNTH-2501 (Ga 68 edotreotide)
LNTH-2501 (Kit for Preparation of Ga 68 edotreotide Injection), is currently under evaluation by the FDA as a radioactive diagnostic kit indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. LNTH-2501 is supplied as a 2-vial kit to radiopharmacies which allows for direct preparation of Ga 68 edotreotide injection with the eluate of Gallium from an on-site generator at the radiopharmacy. LNTH-2501 is not currently approved by the FDA and is not yet available for sale in the United States.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include a delay in obtaining, or failure to obtain, a positive regulatory outcome from the FDA for LNTH-2501 and the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q).
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842 [email protected]
Lantheus (NASDAQ: LNTH - Get Free Report) and High Tide (NASDAQ: HITI - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation. Analyst Recommendations This is a summary of current ratings
Lantheus Holdings faces a three-month FDA PDUFA extension for OCTEVY, delaying potential approval and launch to June 2026. OCTEVY's extension is procedural, tied to manufacturing review, not efficacy or safety, and is not expected to impact its clinical adoption pathway. While OCTEVY alone won't restore double-digit growth, it can stabilize near-term revenue and support LNTH's strategic pivot to PET radiodiagnostics.
Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) have received an average rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $86.1429.
A number of brokerages have recently issued reports on LNTH. William Blair reiterated an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Citizens Jmp boosted their price target on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 24th. Wall Street Zen upgraded shares of Lantheus from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 28th. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Finally, Mizuho boosted their price target on shares of Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a research note on Friday, February 27th.
Read Our Latest Stock Report on Lantheus
Lantheus Price Performance Lantheus stock opened at $80.03 on Thursday. The stock has a market cap of $5.21 billion, a P/E ratio of 23.75 and a beta of -0.12. The company has a fifty day simple moving average of $74.04 and a 200-day simple moving average of $64.68. Lantheus has a 12-month low of $47.25 and a 12-month high of $108.91. The company has a current ratio of 2.70, a quick ratio of 2.51 and a debt-to-equity ratio of 0.52.
Lantheus (NASDAQ:LNTH – Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.50. The business had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts expect that Lantheus will post 6.01 EPS for the current fiscal year.
Institutional Trading of Lantheus A number of institutional investors have recently added to or reduced their stakes in LNTH. Hantz Financial Services Inc. boosted its holdings in Lantheus by 412.5% during the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 396 shares in the last quarter. First Horizon Corp purchased a new stake in Lantheus during the third quarter worth about $26,000. Smartleaf Asset Management LLC boosted its holdings in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares in the last quarter. Parallel Advisors LLC boosted its holdings in Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 298 shares in the last quarter. Finally, Osterweis Capital Management Inc. purchased a new stake in Lantheus during the second quarter worth about $36,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.
Lantheus Company Profile (Get Free Report)
Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.
The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.
Read More Five stocks we like better than Lantheus
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEHudson Technologies, Inc. (NASDAQ:HDSN) Receives Consensus Rating of “Hold” from Analysts
NEXT HEADLINE »Head to Head Comparison: Copa (CPA) versus Its Competitors
Shares of Lantheus Holdings were added after the company received FDA approval of its key product TruVu. We used recent weakness as an opportunity to initiate a position in Talen Energy, an independent power producer whose portfolio includes the Susquehanna nuclear plant and other dispatchable generation assets. We exited Cactus as we lost confidence that its major growth lever, expansion into the Middle East, would play out in 2026 amid the escalating conflict in the region.
BEDFORD, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its first quarter ended March 31, 2026.
Lantheus Holdings Inc (NASDAQ:LNTH) reported upbeat earnings for the first quarter on Thursday.
The company posted quarterly earnings of $1.46 per share which beat the analyst consensus estimate of $1.24 per share. The company reported quarterly sales of $377.330 million which beat the analyst consensus estimate of $353.942 million.
Lantheus Holdings affirmed its FY2026 adjusted EPS guidance of $5.00-$5.25 and sales guidance of $1.400 billion-$1.450 billion.
“Our first quarter results demonstrate disciplined execution across the business, with strong performance from PYLARIFY, Neuraceq, and DEFINITY, and continued progress against the priorities that underpin our long-term strategy,” said Mary Anne Heino, Chief Executive Officer of Lantheus.
Lantheus shares rose 3.1% to trade at $93.85 on Friday.
These analysts made changes to their price targets on Lantheus following earnings announcement.
Mizuho analyst Anthony Petrone maintained the stock with an Outperform rating and raised the price target from $95 to $100. Citizens analyst David Turkaly maintained the stock with a Market Outperform and raised the price target from $85 to $115. Considering buying LNTH stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 SharesMarketBeat
CocaCola Company (The) (NYSE:KO - Get Free Report) EVP Jennifer Mann sold 23,984 shares of the firm's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $83.41, for a total value of $2,000,505.44. Following the completion of the transaction, the executive vice president owned 157,400 shares of the company's stock, valued at approximately $13,128,734. The trade was a 13.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
NYSE:KO
Read CocaCola (NYSE:KO) EVP Jennifer Mann Sells 23,984 Shares
3 hours ago
Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,054 shares of the company's stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $60.37, for a total transaction of $15,759,829.98. Following the completion of the sale, the insider owned 2,671,855 shares in the company, valued at $161,299,886.35. This represents a 8.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
NYSE:BROS
Read Dutch Bros (NYSE:BROS) Major Shareholder Sells $15,759,829.98 in Stock
3 hours ago
Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) major shareholder Dm Individual Aggregator, Llc sold 261,055 shares of the business's stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $63.02, for a total value of $16,451,686.10. Following the completion of the transaction, the insider owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 9.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.
NYSE:BROS
Read Insider Selling: Dutch Bros (NYSE:BROS) Major Shareholder Sells 261,055 Shares of Stock
3 hours ago
Travis Boersma Sells 749,999 Shares of Dutch Bros (NYSE:BROS) StockMarketBeat
Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 749,999 shares of Dutch Bros stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $60.39, for a total transaction of $45,292,439.61. Following the completion of the sale, the chairman owned 2,671,855 shares of the company's stock, valued at $161,353,323.45. This represents a 21.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dutch Bros Inc. (NYSE:BROS - Get Free Report) Chairman Travis Boersma sold 750,000 shares of the company's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $63.02, for a total value of $47,265,000.00. Following the sale, the chairman owned 2,410,800 shares in the company, valued at approximately $151,928,616. This trade represents a 23.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
May 19, 2026 08:30 ET | Source: Lantheus Holdings, Inc.
BEDFORD, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026 in Chicago, IL.
Presentation details are as follows:
Date & Time: Monday, June 1
Session Type: Poster
Session Title: Sarcoma
Poster Number: 376b
Title: A phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary anti-neoplastic activity of LNTH-2403, a LRRC15-targeted 177lutetium-labeled monoclonal antibody, in patients with relapsed/refractory osteosarcoma.
Presenter: Noah Federman, UCLA Jonsson Comprehensive Cancer Center, UCLA David Geffen School of Medicine, Los Angeles, CA
Session Type: Publication Only
Session Title: Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile
Title: Real-world use of piflufolastat F 18 and imaging-associated treatment patterns in early-stage prostate cancer.
First Author: Emma Billmyer, The Analysis Group, Boston, MA
Abstract Number: e17126
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842 [email protected]
May 21, 2026 08:30 ET | Source: Lantheus Holdings, Inc.
BEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced new radiodiagnostic data to be presented at the 2026 Society of Nuclear Medicine and Medical Imaging (SNMMI) Annual Meeting, taking place May 30 – June 2, 2026 in Los Angeles, CA.
Presentation details are as follows:
Date & Time: Monday, June 1, 2026, 10:30 am – 11:15 am PT
Session Number: MTA06 – Screen 29
Title: Impact of PSMA-PET with Piflufolastat F18 on Prostate Cancer Management for Patients with Low or Ultra-low Prostate-Specific Antigen Levels after Definitive Treatment.
Presenter: Neal Shore, Carolina Urologic Research Center
Poster Number: #262453
Date & Time: Tuesday, June 2, 2026, 9:50 am – 10:00 am PT
Session Type: Oral Presentation
Session Title: Prognosis and Novel Imaging Techniques
Session Number: SS30
Location: SS Room 2
Title: Diagnostic performance of 18F-GP1 PET/CT for acute deep vein thrombosis of the lower extremities in symptomatic patients: a phase 2, open-label, non-randomized study
Presenter: Sangwon Han, Asan Medical Center, University of Ulsan College of Medicine
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842 [email protected]
U.S. dollar banknotes are seen in this illustration taken March 24, 2026. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
CompaniesMay 22 (Reuters) - Radiopharmaceutical-focused company Lantheus Holdings (LNTH.O), opens new tab is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that values it at about $7 billion, Bloomberg News reported on Friday.
The two companies have been in discussions about a potential deal that could be weeks away, the report said, citing people familiar with the matter. No final decision has been made and there is no guarantee the talks will result in a transaction, the report said.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Lantheus declined to comment. Shares of the company, which has a market capitalization of about $6.15 billion, were trading nearly 2% down in extended trading.
Curium was valued at about $7 billion last year when its owner, CapVest Partners, raised funds for a continuation vehicle for the nuclear medicine company, the report said. Curium did not respond to a Reuters request for comment.
Lantheus beat analysts' expectations for first-quarter adjusted profit earlier this month, helped by demand for its cancer imaging agent.
"2026 is a year of commercial execution and regulatory milestones," said interim CEO Mary Heino on the earnings call. "We're making deliberate choices about where we focus our commercial efforts and deploying capital, so we're positioned to deliver solid results in 2026 and accelerate growth in 2027."
Lantheus, however, reiterated its annual earnings forecast, while the company acknowledged, according to a William Blair analyst, that an upward revision is overdue but will not occur until a permanent CEO is appointed.
In March, the U.S. FDA extended its review of Lantheus' diagnostic imaging kit, LNTH-2501, by three months to allow more time to assess manufacturing-related information. The decision is now expected by June 29.
Separately in March, the regulator approved a new formulation of the company's prostate cancer imaging agent, Pylarify, aimed at expanding scanning access through increased production capacity.
Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar
Our Standards: The Thomson Reuters Trust Principles., opens new tab
May 27, 2026 08:30 ET | Source: Lantheus Holdings, Inc.
BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the William Blair 46th Annual Growth Stock Conference at 12:10 p.m. ET on Wednesday, June 3.
To access the live webcast of the presentations, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentation.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842 [email protected]
BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that an image generated using LNTH-2513 (18F-GP1) PET/CT was awarded SNMMI’s Image of the Year at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting in Los Angeles, California. The recognition was presented in connection with investigator-initiated trial results evaluating LNTH-2513 PET/CT for the detection of acute lower-extremity deep vein thrombosis (DVT) in symptomatic patients.
"These results demonstrate the potential of 18F-GP1 PET/CT as a thrombus-specific imaging approach," said Dr. Sangwon Han, lead investigator and Professor of Nuclear Medicine at Asan Medical Center. "In this study, 18F-GP1 PET/CT showed high diagnostic accuracy for proximal DVT and detected thrombi in areas that may be difficult to assess with conventional imaging."
LNTH-2513 (18F-GP1) is an investigational fluorine-18-labeled PET imaging agent that selectively binds to glycoprotein IIb/IIIa receptors on activated platelets, enabling direct visualization of active thrombus formation. In the investigator-initiated open-label, non-randomized study, LNTH-2513 was evaluated in 46 patients with clinically suspected acute lower-extremity DVT. Patients underwent PET/CT approximately 120 minutes after intravenous administration of LNTH-2513, and results were compared with venous ultrasonography (VUS), the reference standard, performed within seven days of PET/CT.
Study results presented with the award-winning image include:
LNTH-2513 demonstrated high diagnostic accuracy for proximal DVT, with patient-based sensitivity of 95% (95% CI: 77-100) and specificity of 92% (95% CI: 73-99).For distal DVT, LNTH-2513 demonstrated positive percent agreement of 96% (95% CI: 80-100) and negative percent agreement of 90% (95% CI: 68-99) versus venous ultrasonography.Qualitative interpretation of LNTH-2513 PET/CT demonstrated high inter-reader agreement for patient-based assessment of proximal and distal DVT, as well as for vessel-based analysis.LNTH-2513 identified concomitant pulmonary embolism in 22 of 46 patients, including 19 of 22 patients with proximal DVT, 2 of 6 patients with isolated distal DVT, and 1 of 18 patients without DVT on venous ultrasonography.LNTH-2513 was well tolerated, with no drug-related adverse events reported. "This recognition from SNMMI highlights the compelling imaging capabilities of LNTH-2513 and the potential of thrombus-specific PET/CT to advance how thromboembolic disease is visualized and understood," said Andrew Stephens, M.D., Ph.D., Senior Vice President, Clinical Development, Lantheus.
About Deep Vein Thrombosis
Deep vein thrombosis is a significant cause of vascular-related morbidity and mortality and can lead to serious complications, including pulmonary embolism. While venous ultrasonography is the current standard of care, it can be limited in detecting thrombi in certain anatomical regions, including calf veins and deeper pelvic vessels.
About LNTH-2513 (18F-GP1)
LNTH-2513 (GP1) is a small F-18 labeled molecule, specifically designed to image active thrombi (new blood clots) by binding to activated GPllb/llla receptors, which are involved in thrombus formation and propagation.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for more than 70 years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as "explore,” “opportunity,” “potential,” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) our ability to successfully continue existing clinical development of LNTH-2513; (ii) the timing and potential outcomes of clinical studies using LNTH-2513; (iii) a delay in obtaining, or failure to obtain, a positive regulatory outcome from the FDA and other regulatory authorities for LNTH-2513; (iv) our ability to launch LNTH-2513 as a commercial product; (v) the market receptivity to LNTH-2513 as a radiopharmaceutical diagnostic; (vi) the existence, availability and profile of competing products; (vii) our ability to obtain and maintain adequate coding, coverage and payment for LNTH-2513; (viii) the safety and efficacy of LNTH-2513; (ix) the intellectual property protection of LNTH-2513; (x) our ability to successfully develop and scale the manufacturing capabilities to support the launch of LNTH-2513; and (xi) the risks and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q).
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842 [email protected]
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3988bfe4-910b-46c7-aa87-a697af87a66d
Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year (Left) 18F-GP1 PET/CT images from a 75-year-old woman show multiple blood clots in the deep veins of...
June 03, 2026 08:30 ET | Source: Lantheus Holdings, Inc.
BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced John Wiggins, Vice President, External Manufacturing, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 9.
To access the live webcast of the presentations, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentation.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842 [email protected]
